The primary objective is to determine the efficacy of ST266 eye drops in healing persistent epithelial defects (PED). After 8 weeks of randomized, double-blind treatment, non-healers will enter into an additional 8-week open-label ST266 treatment period. All patients will be followed for 3-months post-treatment for monitoring of safety and maintenance of re-epithelialization.
• Subjects with a PED present for greater than 7 days
• Subjects with PED greater than 1.00mm
• Cornea defect is result of injury, infection, disease, or surgery to eye
Currently being treated with cenegermin or other RHNGF in study eye; bullous keratopathy in study eye, require serum tears
Up to 29 weeks: 1-week Washout/Screening Period; 8-week Randomized, Double-Blind Treatment; 8-week Open-Label ST266 Treatment Extension; 12 week Post Treatment Follow-Up